We are live on
!
Find out more
SCM
Squadron Capital Management Portfolio holdings
AUM
$322M
This Fund
S&P 500
This Quarter
Est. Return
+122.93%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$236M
AUM Growth
–
Cap. Flow
+$190M
Cap. Flow
% of AUM
80.72%
Top 10 Holdings %
Top 10 Hldgs %
65.68%
Holding
33
New
33
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Relmada Therapeutics
RLMD
|
+$22.4M |
| 2 |
Cogent Biosciences
COGT
|
+$21.9M |
| 3 |
MAZE
Maze Therapeutics
MAZE
|
+$16.8M |
| 4 |
ABVX
Abivax
ABVX
|
+$15.8M |
| 5 |
KALV
KalVista Pharmaceuticals
KALV
|
+$9.27M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Relmada Therapeutics
RLMD
$489M
| $32.4M | 13.71% |
+6,700,000
| New | +$22.4M |
|
|
2
Cogent Biosciences
COGT
$6.29B
| $27.7M | 11.74% |
+780,000
| New | +$21.9M |
|
|
MAZE
3
Maze Therapeutics
MAZE
$1.64B
| $20.3M | 8.6% |
+490,000
| New | +$16.8M |
|
|
ABVX
4
Abivax
ABVX
$10.1B
| $19.6M | 8.29% |
+145,000
| New | +$15.8M |
|
|
KALV
5
DELISTED
KalVista Pharmaceuticals
KALV
| $11.3M | 4.79% |
+700,000
| New | +$9.27M |
|
6
Palisade Bio
PALI
$350M
| $10.6M | 4.48% |
+4,500,000
| New | +$8.65M |
|
7
Edgewise Therapeutics
EWTX
$4.86B
| $8.69M | 3.68% |
+350,000
| New | +$7.03M |
|
8
Inhibikase Therapeutics
IKT
$349M
| $8.66M | 3.67% |
+4,225,000
| New | +$6.72M |
|
9
Kodiak Sciences
KOD
$2.34B
| $8.16M | 3.46% |
+291,710
| New | +$5.97M |
|
|
TERN
10
DELISTED
Terns Pharmaceuticals
TERN
| $7.68M | 3.25% |
+190,000
| New | +$4.39M |
|
11
CALL
ArriVent BioPharma
AVBP
$1.39B
| $6.8M | 2.88% |
+338,000
| New | +$7.04M |
|
12
Tarsus Pharmaceuticals
TARS
$3.2B
| $6.55M | 2.78% |
+80,000
| New | +$5.97M |
|
|
UPB
13
Upstream Bio Inc
UPB
$362M
| $6.26M | 2.65% |
+230,650
| New | +$5.74M |
|
|
SPRB
14
Spruce Biosciences
SPRB
$169M
| $6.1M | 2.58% |
+70,000
| New | +$7.5M |
|
15
Xenon Pharmaceuticals
XENE
$5.86B
| $4.73M | 2% |
+105,551
| New | +$4.43M |
|
|
DBVT
16
DBV Technologies
DBVT
$889M
| $4.6M | 1.95% |
+240,000
| New | +$3.75M |
|
|
HELP
17
Cybin Inc
HELP
$951M
| $4.29M | 1.82% |
+525,000
| New | +$3.38M |
|
18
Lipocine
LPCN
$17M
| $4.26M | 1.8% |
+530,000
| New | +$1.78M |
|
|
BLTE
19
Belite Bio
BLTE
$6.4B
| $4.16M | 1.76% |
+26,000
| New | +$3.08M |
|
20
GH Research
GHRS
$1.93B
| $4M | 1.7% |
+315,000
| New | +$4.29M |
|
|
EPRX
21
Eupraxia Pharmaceuticals
EPRX
$481M
| $3.77M | 1.6% |
+500,000
| New | +$3.08M |
|
|
VTYX
22
DELISTED
Ventyx Biosciences
VTYX
| $3.7M | 1.57% |
+410,000
| New | +$3.06M |
|
23
NextCure
NXTC
$27M
| $3.36M | 1.43% |
+236,966
| New | +$2.46M |
|
24
CALL
Vera Therapeutics
VERA
$2.43B
| $3.04M | 1.29% |
+60,000
| New | +$2.13M |
|
25
Wave Life Sciences
WVE
$1.01B
| $2.98M | 1.26% |
+175,000
| New | +$1.78M |
|
Similar funds
SST
CW
WW
NAG
JGIA
EI
KF
QFPS
Squadron Capital Management's Q4 2025 Portfolio in Review
Q4 2025 is the first quarter with a 13F filing on record for Squadron Capital Management, which disclosed 33 positions worth $236M. Its ten largest holdings account for 66% of the portfolio.
Its largest position is Relmada Therapeutics: 6,700,000 shares worth $32.4M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets.
- Squadron Capital Management's largest Q4 2025 buy was Relmada Therapeutics: 6,700,000 shares worth $32.4M.
- Squadron Capital Management's ten largest holdings make up 66% of its $236M portfolio in Q4 2025.
- Squadron Capital Management disclosed 33 positions in Q4 2025, its first 13F filing on record.
Based on Squadron Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.